Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT)
this morning announced its entrance into a definitive agreement with SoluBest
Ltd. to acquire the worldwide rights for the use, development and
commercialization of its patented Solumer™ Oral Drug Delivery Technology. The
innovative technology will be employed to improve the bioavailability, delivery
and commercialization of biocannabis-based products. The delivery technology
also encompasses SoluCBD and SoluTHC, ingredients for a new category of
cannabis-infused non-alcoholic beverages. “The addition of Solumer™ further
positions us to collaborate with multinational companies to introduce
non-alcoholic cannabis-infused beverages to consumers. Pivot has the largest
portfolio of platform technologies for the formulation and delivery of
cannabinoids in the cannabis space,” Pivot Pharmaceuticals CEO Dr. Patrick
Frankham stated in the news release. “As we prepare to bring Pivot’s industry
leading pipeline of derivatives to market, we continue to aggressively execute
on our business plan.”
To view the full press release, visit http://ibn.fm/P5sZH
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is a biopharmaceutical company
engaged in the development and commercialization of therapeutic pharmaceuticals
and nutraceuticals using innovative drug delivery platform technologies.
Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream
Health Solutions Inc. (“PGS”), conducts research, development and
commercialization of cannabinoid-based nutraceuticals and pharmaceuticals.
Pivot’s wholly-owned U.S. subsidiary, Pivot Naturals, LLC, based in Costa Mesa,
California, will manufacture and supply finished powderized cannabis products
such as food additives, capsules, bulk powder and stick packs to the California
market. PGS has acquired worldwide rights to Ready-To-Infuse Cannabis (“RTIC”)
oil-to-powder technology, BiPhasix™ Dermal Drug Delivery platform technology
(topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal
Nanotechnology (transdermal) for the delivery and commercialization of
cannabinoid, cannabidiol (“CBD”), and tetrahydrocannabinol (“THC”)-based
products. For more information, visit the company’s website at www.PivotPharma.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment